title: Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors.
abstract: The latest influenza A (H1N1) pandemic attracted worldwide attention and called for the urgent development of novel antiviral drugs. Here, seven tripeptides are designed and explored as neuraminidase (NA) inhibitors on the structural basis of known inhibitors. Their interactions with NA are studied and compared with each other, using flexible docking and molecular dynamics simulations. The various composed tripeptides have respective binding specificities and their interaction energies with NA decrease in the order of FRI > FRV > FRT > FHV > FRS > FRG > YRV (letters corresponding to amino acid code). The Arg and Phe portions of the tripeptides play important roles during the binding process: Arg has strong electrostatic interactions with the key residues Asp151, Glu119, Glu227 and Glu277, whereas Phe fits well in the hydrophobic cave within the NA active site. Owing to the introduction of hydrophobic property, the interaction energies of FRV and FRI are larger; in particular, FRI demonstrates the best binding quality and shows potential as a lead compound. In addition, the influence of the chemical states of the terminal amino acids are clarified: it is revealed that the charged states of the N-terminus (NH(3) (+)) and C-terminus (COO(-)) are crucial for the tripeptide inhibitory activities and longer peptides may not be appropriate. In addition, the medium inhibiting activity by acetylation of the N-terminus indicates the possible chemical modifications of FRI. Experimental efforts are expected in order to actualize the tripeptides as potent NA inhibitors in the near future.
authors: Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin 150040, China; E-Mails: yzws-123@163.com (Z.Y.); fuyujie1967@yahoo.com.cn (Y.F.); zlj_1008@yahoo.com.cn (L.Z.).
authors: Zhiwei
authors: Z
authors: Yang
authors: Gang
authors: G
authors: Yang
authors: Yuangang
authors: Y
authors: Zu
authors: Yujie
authors: Y
authors: Fu
authors: Lijun
authors: L
authors: Zhou
references: Int J Mol Sci. 2009 Sep 07;10(9):3918-30
references: 19865525
references: J Am Chem Soc. 2005 Dec 7;127(48):17079-89
references: 16316255
references: J Med Chem. 1999 Dec 16;42(25):5142-52
references: 10602699
references: N Engl J Med. 2005 Dec 22;353(25):2667-72
references: 16371632
references: J Mol Graph Model. 2005 Oct;24(2):147-56
references: 16098779
references: Interdiscip Sci. 2009 Sep;1(3):196-203
references: 20640838
references: J Theor Biol. 2010 Dec 7;267(3):363-74
references: 20831875
references: Annu Rev Med. 2008;59:397-413
references: 17939760
references: Curr Drug Targets Cardiovasc Haematol Disord. 2001 Jun;1(1):41-9
references: 12769663
references: Nat Struct Mol Biol. 2010 May;17(5):530-8
references: 20383144
references: J Virol. 2005 Sep;79(18):11588-97
references: 16140736
references: J Phys Chem B. 2008 Jun 12;112(23):7104-10
references: 18479160
references: Nat Rev Drug Discov. 2003 Jul;2(7):587-93
references: 12815383
references: Protein Sci. 2001 Apr;10(4):689-96
references: 11274459
references: Biochemistry. 2003 Jan 28;42(3):718-27
references: 12534284
references: Science. 2008 Nov 21;322(5905):1257-9
references: 19023083
references: J Am Chem Soc. 2009 Apr 8;131(13):4702-9
references: 19296611
references: N Engl J Med. 2005 Sep 29;353(13):1363-73
references: 16192481
references: Nature. 2009 Aug 20;460(7258):1021-5
references: 19672242
references: Nature. 1993 Jun 3;363(6428):418-23
references: 8502295
references: J Phys Chem B. 2009 Aug 6;113(31):10957-64
references: 19591510
references: Biomed Pharmacother. 2003 May-Jun;57(3-4):145-55
references: 12818476
references: J Virol. 2006 Dec;80(24):11960-7
references: 17005658
references: Nature. 1983 May 5-11;303(5912):41-4
references: 6188957
references: Protein Sci. 2004 Apr;13(4):946-57
references: 15044728
references: Acc Chem Res. 2008 Jan;41(1):50-9
references: 18193821
references: J Med Chem. 2002 May 23;45(11):2207-12
references: 12014958
references: J Med Chem. 2003 Dec 18;46(26):5628-37
references: 14667217
references: Virol J. 2009 Jun 05;6:74
references: 19497129
references: J Phys Chem B. 2009 Apr 9;113(14):4899-906
references: 19281166
references: Phys Chem Chem Phys. 2009 Nov 21;11(43):10035-41
references: 19865756
references: J Med Chem. 2009 Jul 23;52(14):4247-56
references: 19558186
references: Ann N Y Acad Sci. 2003 Jun;994:133-40
references: 12851308
references: Structure. 1998 Jun 15;6(6):735-46
references: 9655825
references: Antiviral Res. 2008 Apr;78(1):91-102
references: 18328578
references: Nat Biotechnol. 2006 Feb;24(2):177-83
references: 16465163
references: Nature. 2006 Sep 7;443(7107):45-9
references: 16915235
references: J Am Chem Soc. 1997 Jan 29;119(4):681-90
references: 16526129
references: Biophys J. 2007 Feb 1;92(3):798-807
references: 17085491
references: Virus Res. 2004 Jul;103(1-2):199-203
references: 15163510
references: Drug Discov Today. 2004 Jun 1;9(11):470
references: 15149618
references: Protein Sci. 1994 Oct;3(10):1687-96
references: 7849585
references: J Phys Chem B. 2008 May 1;112(17):5470-8
references: 18399682
references: Nat Rev Drug Discov. 2007 Dec;6(12):967-74
references: 18049471
references: Trends Pharmacol Sci. 2007 Jun;28(6):280-5
references: 17481739
references: Protein Sci. 1995 Jun;4(6):1081-7
references: 7549872
references: N Engl J Med. 2010 May 6;362(18):1708-19
references: 20445182
references: J Antimicrob Chemother. 2005 Feb;55 Suppl 1:i5-i21
references: 15709056
references: Biopolymers. 1996;40(2):235-44
references: 8785365
references: Curr Drug Targets. 2004 Feb;5(2):119-36
references: 15011946